EA036178B1 - Процесс контроля уровня содержания гликанов в составе гликопротеинов - Google Patents

Процесс контроля уровня содержания гликанов в составе гликопротеинов Download PDF

Info

Publication number
EA036178B1
EA036178B1 EA201791223A EA201791223A EA036178B1 EA 036178 B1 EA036178 B1 EA 036178B1 EA 201791223 A EA201791223 A EA 201791223A EA 201791223 A EA201791223 A EA 201791223A EA 036178 B1 EA036178 B1 EA 036178B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
cell
culture
cell culture
perfusion
Prior art date
Application number
EA201791223A
Other languages
English (en)
Russian (ru)
Other versions
EA201791223A1 (ru
Inventor
Дэниел Р. Лейске
Майкл Т. Тренталанж
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA036178(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201791223A1 publication Critical patent/EA201791223A1/ru
Publication of EA036178B1 publication Critical patent/EA036178B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201791223A 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе гликопротеинов EA036178B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01
PCT/US2015/063271 WO2016089919A1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Publications (2)

Publication Number Publication Date
EA201791223A1 EA201791223A1 (ru) 2017-10-31
EA036178B1 true EA036178B1 (ru) 2020-10-09

Family

ID=55024253

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791223A EA036178B1 (ru) 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе гликопротеинов
EA202091598A EA202091598A3 (ru) 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202091598A EA202091598A3 (ru) 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе

Country Status (22)

Country Link
US (6) US10167492B2 (https=)
EP (2) EP3227454B1 (https=)
JP (4) JP6698681B2 (https=)
KR (1) KR102623965B1 (https=)
CN (1) CN107109455B (https=)
AU (5) AU2015355087C1 (https=)
CA (1) CA2969225C (https=)
CL (1) CL2017001369A1 (https=)
CY (1) CY1123247T1 (https=)
DK (1) DK3227454T3 (https=)
EA (2) EA036178B1 (https=)
ES (1) ES2784503T3 (https=)
HU (1) HUE049201T2 (https=)
IL (2) IL276165B (https=)
LT (1) LT3227454T (https=)
MX (1) MX385409B (https=)
PL (1) PL3227454T3 (https=)
PT (1) PT3227454T (https=)
SG (2) SG10202002458PA (https=)
SI (1) SI3227454T1 (https=)
WO (1) WO2016089919A1 (https=)
ZA (2) ZA201703729B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
EP3397282A4 (en) 2015-12-30 2019-08-07 Momenta Pharmaceuticals, Inc. METHODS RELATING TO BIOLOGICA
AU2018235928B2 (en) * 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
AU2018241849B2 (en) * 2017-03-31 2023-06-22 Boehringer Ingelheim International Gmbh Perfusion medium
WO2019105444A1 (zh) * 2017-11-30 2019-06-06 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
BR112020019559A2 (pt) 2018-03-26 2021-01-12 Amgen Inc. Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
AU2019274782A1 (en) * 2018-05-24 2020-12-03 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
US20210155710A1 (en) 2018-06-05 2021-05-27 Amgen Inc. Modulating antibody dependent cellular phagocytosis
AU2019336148B2 (en) 2018-09-06 2025-08-14 Momenta Pharmaceuticals, Inc. Methods of continuous cell culture
MX2021002792A (es) 2018-09-11 2021-05-12 Amgen Inc Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
EA202191352A1 (ru) 2018-11-13 2021-08-11 Янссен Байотек, Инк. Контроль содержания микроэлементов-металлов во время продукции антител к cd38
WO2020142275A1 (en) * 2018-12-31 2020-07-09 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
CA3127228A1 (en) * 2019-01-30 2020-08-06 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
AU2020268442A1 (en) 2019-05-06 2021-11-25 One Amgen Center Drive Law - Patent Operations Modulating antibody effector functions
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
US12529024B2 (en) 2019-11-15 2026-01-20 Lonza Ltd Process and system for producing an inoculum
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same
US20230313259A1 (en) * 2020-08-14 2023-10-05 Bristol-Myers Squibb Company Manufacturing process for protein
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2023223660A1 (en) * 2022-02-25 2024-08-01 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
CN121712803A (zh) * 2023-08-16 2026-03-20 葛兰素史密斯克莱知识产权有限公司 控制抗体糖基化谱的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120276631A1 (en) * 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013114245A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP3029062A1 (en) 2000-05-26 2016-06-08 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
EP3026109B1 (en) 2005-12-08 2022-03-09 Amgen Inc. Improved production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
WO2008121757A1 (en) * 2007-03-30 2008-10-09 Centocor Inc High expression clones of mammalian cells with fluorescent protein a or g
EP2528002B1 (en) 2007-04-16 2015-11-04 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
PT2173861E (pt) 2007-06-15 2011-05-13 Amgen Inc M?todos de tratamento de meios de cultura de c?lulas para utiliza??o num biorreactor
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20120164137A1 (en) * 2010-10-20 2012-06-28 Morphotek, Inc. Anti-folate receptor alpha antibody glycoforms
KR20130129438A (ko) 2011-02-23 2013-11-28 암젠 인크 Uvc 노출을 위한 세포 배양 배지 및 이와 관련된 방법
WO2012120500A2 (en) * 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
DK2726600T3 (en) 2011-07-01 2017-05-15 Amgen Inc Mammalian Cell Culture
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
TWI583788B (zh) 2011-09-16 2017-05-21 安美基公司 細胞培養之預程式化無回饋控制之連續進料
EA201992617A1 (ru) 2011-10-26 2020-03-10 Амген Инк. Способы уменьшения или устранения модификации и разложения белка, обусловленных воздействием уф-излучения
CN104487570A (zh) * 2012-01-20 2015-04-01 新加坡科技研究局 Cho-gmt重组蛋白的表达
WO2013138159A1 (en) 2012-03-15 2013-09-19 Amgen Inc. Methods of determining exposure to uv light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
US9714291B2 (en) * 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
KR102062784B1 (ko) 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
HRP20200100T1 (hr) * 2014-02-27 2020-04-03 F. Hoffmann - La Roche Ag Modulacija rasta i glikozilacije stanica u rekombinantnoj proizvodnji glikoproteina
SG11201702964UA (en) * 2014-10-27 2017-05-30 Agency Science Tech & Res Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120276631A1 (en) * 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013114245A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRAMER M J, ECKBLAD J J, DONAHUE R, BROWN J, SHULTZ C, VICKERMAN K, PRIEM P, VAN DEN BREMER E T, GERRITSEN J, VAN BERKEL P H: "Modulation of Antibody Galactosylation Through Feeding of Uridine, Manganese Chloride, and Galactose", BIOTECHNOLOGY AND BIOENGINEERING, WILEY, US, vol. 108, no. 7, 1 July 2011 (2011-07-01), US, pages 1591 - 1602, XP002688515, ISSN: 0006-3592, DOI: 10.1002/bit.23075 *

Also Published As

Publication number Publication date
PT3227454T (pt) 2020-04-06
AU2025223948A1 (en) 2025-09-18
US20200172947A1 (en) 2020-06-04
US20210017565A1 (en) 2021-01-21
CY1123247T1 (el) 2021-10-29
SG11201704351WA (en) 2017-06-29
LT3227454T (lt) 2020-07-27
IL252569A0 (en) 2017-07-31
JP2022101669A (ja) 2022-07-06
HUE049201T2 (hu) 2020-09-28
CA2969225C (en) 2023-08-22
JP7066775B2 (ja) 2022-05-13
US20230159974A1 (en) 2023-05-25
EA202091598A2 (ru) 2020-10-30
IL252569B (en) 2020-08-31
ZA202006002B (en) 2022-03-30
EA202091598A3 (ru) 2021-01-29
US20260110013A1 (en) 2026-04-23
AU2022200586A1 (en) 2022-02-24
KR102623965B1 (ko) 2024-01-11
CN107109455A (zh) 2017-08-29
CN107109455B (zh) 2022-02-18
ZA201703729B (en) 2021-03-31
PL3227454T3 (pl) 2020-07-27
JP6698681B2 (ja) 2020-05-27
EP3227454B1 (en) 2020-01-29
BR112017011652A2 (pt) 2018-06-26
US10822630B2 (en) 2020-11-03
IL276165A (en) 2020-09-30
CA2969225A1 (en) 2016-06-09
SI3227454T1 (sl) 2020-06-30
AU2015355087C1 (en) 2025-10-30
JP2017538446A (ja) 2017-12-28
EP3680344A1 (en) 2020-07-15
AU2015355087B2 (en) 2020-04-09
SG10202002458PA (en) 2020-04-29
JP2024095777A (ja) 2024-07-10
EA201791223A1 (ru) 2017-10-31
IL276165B (en) 2022-11-01
MX385409B (es) 2025-03-04
AU2015355087A1 (en) 2017-06-29
US20190085370A1 (en) 2019-03-21
WO2016089919A1 (en) 2016-06-09
AU2024204313A1 (en) 2024-07-11
MX2017006997A (es) 2017-10-16
DK3227454T3 (da) 2020-04-14
US10167492B2 (en) 2019-01-01
EP3227454A1 (en) 2017-10-11
KR20170083636A (ko) 2017-07-18
AU2020202302A1 (en) 2020-04-23
CL2017001369A1 (es) 2018-02-23
ES2784503T3 (es) 2020-09-28
JP2020124216A (ja) 2020-08-20
US20170362625A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
US20230159974A1 (en) Process for manipulating the level of glycan content of a glycoprotein
US11427848B2 (en) Methods for harvesting mammalian cell cultures
HK40034016A (en) Process for manipulating the level of glycan content of a glycoprotein
HK40065682B (en) Methods for harvesting mammalian cell cultures
HK40065682A (en) Methods for harvesting mammalian cell cultures
BR112017011652B1 (pt) Método para manipulação do nível de teor de glicano fucosilado em uma proteína recombinante
HK1236575B (en) Methods for harvesting mammalian cell cultures
HK1236575A1 (en) Methods for harvesting mammalian cell cultures

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM